Net Assets for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported net assets is $789.18M USD. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingNet AssetsSwitch metric
Latest period
$789.18M
YoY change
+1076.3%
5Y CAGR
-4.9%
Peak year (2017)
$1.77B
Latest annual
$789.18M
Net Assets history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Net Assets history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Net Assets | YoY |
|---|---|---|---|---|
| 2025 | $789.18M | +1076.3% | ||
| 2024 | $67.09M | -130.4% | ||
| 2023 | -$220.64M | +39.5% | ||
| 2022 | -$158.22M | -126.9% | ||
| 2021 | $588.20M | -42.1% | ||
| 2020 | $1.02B | -29.4% | ||
| 2019 | $1.44B | +10.5% | ||
| 2018 | $1.30B | -26.3% | ||
| 2017 | $1.77B | +92.0% | ||
| 2016 | $920.22M | -27.2% | ||
| 2015 | $1.26B | +35.1% | ||
| 2014 | $936.27M | +246.3% | ||
| 2013 | $270.35M | +101.7% | ||
| 2012 | $134.05M | +13.6% | ||
| 2011 | $118.00M | -25.4% | ||
| 2010 | $158.23M | -11.1% | ||
| 2009 | $177.97M | -12.0% | ||
| 2008 | $202.13M | +1.5% | ||
| 2007 | $199.17M | -1.0% | ||
| 2006 | $201.17M | +225.6% | ||
| 2005 | $61.78M | +33.9% | ||
| 2004 | $46.14M | -272.8% | ||
| 2003 | -$26.71M | +474.8% | ||
| 2002 | -$4.65M | — |
Net Assets values are taken from Alnylam Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Alnylam Pharmaceuticals (ALNY) net assets totalled $789.18M – surged 1076.3% year-over-year.
Across 2020–2025 (5 years), Alnylam Pharmaceuticals net assets produced a CAGR of -4.9% – sustaining 2 straight years of year-over-year growth.
Alnylam Pharmaceuticals net assets plunged from $1.77B in 2017 to $789.18M in 2025, a 55.3% drawdown.
Across the available history, net assets reached its high of $1.77B in 2017 and its low of -$220.64M in 2023.
Alnylam Pharmaceuticals (ALNY) sits 8th of 8 Healthcare peers we track on this metric, against a peer median of $50.64B.
Alnylam Pharmaceuticals Net Assets by Year
Alnylam Pharmaceuticals Net Assets 2025: $789.18M
Alnylam Pharmaceuticals net assets in 2025 was $789.18M, surged 1076.3% from 2024.
Alnylam Pharmaceuticals Net Assets 2024: $67.09M
Alnylam Pharmaceuticals net assets in 2024 was $67.09M, plunged 130.4% below 2023.
Alnylam Pharmaceuticals Net Assets 2023: -$220.64M
Alnylam Pharmaceuticals net assets in 2023 was -$220.64M, surged 39.5% from 2022. This figure represents the lowest annual value in the available history.
Alnylam Pharmaceuticals Net Assets 2022: -$158.22M
Alnylam Pharmaceuticals net assets in 2022 was -$158.22M, plunged 126.9% below 2021.
Alnylam Pharmaceuticals Net Assets 2021: $588.20M
Alnylam Pharmaceuticals net assets in 2021 was $588.20M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Net Assets
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest net assets.
| Company | Net Assets | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $194.05B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $94.11B | Healthcare |
| Johnson & Johnson (JNJ) | $81.54B | Healthcare |
| Merck & Co., Inc. (MRK) | $52.61B | Healthcare |
| AstraZeneca PLC (AZN) | $48.67B | Healthcare |
| Eli Lilly and Company (LLY) | $26.54B | Healthcare |
| Amgen Inc. (AMGN) | $8.66B | Healthcare |
| AbbVie Inc. (ABBV) | -$3.27B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's net assets?
- Latest reported net assets for Alnylam Pharmaceuticals (ALNY) is $789.18M (period ending December 31, 2025).
How has Alnylam Pharmaceuticals net assets changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) net assets changed +1076.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Alnylam Pharmaceuticals net assets?
- Alnylam Pharmaceuticals (ALNY) net assets compound annual growth rate is -4.9% over the most recent 5 years available.
When did Alnylam Pharmaceuticals net assets hit its highest annual value?
- Alnylam Pharmaceuticals net assets reached its highest annual value of $1.77B in 2017.
What was Alnylam Pharmaceuticals net assets in 2024?
- Alnylam Pharmaceuticals (ALNY) net assets in 2024 was $67.09M.
What was Alnylam Pharmaceuticals net assets in 2025?
- Alnylam Pharmaceuticals (ALNY) net assets in 2025 was $789.18M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.